Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Letter to the Editor Regarding "A Narrative Review of the Vulvar Disease Literature With Images of Women of Color".
J Low Genit Tract Dis
January 2025
Department of Pathology, Immunology, & Laboratory Medicine, Rutgers New Jersey Medical School, Newark, J
Response to: Letter to the editor concerning "Effects of Levetiracetam and Lacosamide on survival and seizure control in 2IDH-wild type glioblastoma during temozolomide plus radiation adjuvant therapy" by Andrea Bianconi et al.
Brain Spine
October 2024
Neurosurgery Unit, "Città della Salute e della Scienza" University Hospital, Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124, Turin, Italy.
Letter to the editor "In-depth assessment of quality of life and real life impact of mild traumatic brain injury in elderly by means of a focus group study".
Brain Spine
October 2024
Centre for Global Health Research, Saveetha Medical Collage and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, 600077, India.
Bosutinib for the Treatment of CML-Using it Safely: a Podcast.
Target Oncol
January 2025
Division of Hematology and SCT, Georgia Cancer Centre, Augusta, GA, USA.
Bosutinib is a second-generation tyrosine kinase inhibitor (TKI) approved for use in patients with newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase (CP) chronic myeloid leukemia (CML), as well as Ph-positive CP, accelerated phase, or blast phase (with chemotherapy) CML resistant or intolerant to prior therapy. Clinical trials have shown bosutinib is effective as first-line therapy for patients with CML as well as in later lines of therapy after prior TKI failure. Bosutinib has an established safety profile; however, as with all TKIs approved for the treatment of CML, there are adverse events (AEs) that require management.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!